BEGIN ARTICLE PREVIEW:
Glen Nowak, director of the Center for Health and Risk Communication at the University of Georgia, co-authored a Perspective article addressing one of the most pressing topics facing the United States: achieving high acceptance of a vaccine for COVID-19.
The article, “When Will We Have a Vaccine? — Understanding Questions and Answers about Covid-19 Vaccination,” was published Sept. 8 in the New England Journal of Medicine. It is co-authored by Barry R. Bloom of the Harvard T.H. Chan School of Public Health, and Walter Orenstein of the Emory Vaccine Center at Emory University School of Medicine.
The Perspective calls attention to the activities and outcomes that need to be achieved before a COVID-19 vaccine is recommended and available for use in the United States. It notes that many people, including health care providers and journalists, are asking, “When will we have a vaccine to protect us against COVID-19?” Nowak and his co-authors point out those who ask that question really are asking three questions:
When will the public be able to have confidence that available COVID-19 vaccines are safe and effective?
When will a COVID-19 vaccine be available to the general public?
When will COVID-19 vaccination rates be high enough that …
END ARTICLE PREVIEW